10 source-reviewed stories · Drugs & supplements
What can medicines and supplements actually show?
Compare medicines, experimental compounds, and supplements while keeping formulation, population, outcome, and regulatory context visible.
Newest coverage
Vitamin D is essential. VITAL still found no broad prevention benefit
In generally healthy adults, vitamin D3 did not significantly reduce invasive cancer, major cardiovascular events, or fractures; deficiency treatment is a different question.
All 10 stories
Every published story in this category
Newest first, using each story’s primary category. Evidence scope describes what was reviewed; it is not a score.
Vitamin D is essential. VITAL still found no broad prevention benefit
In generally healthy adults, vitamin D3 did not significantly reduce invasive cancer, major cardiovascular events, or fractures; deficiency treatment is a different question.
Human clinical outcomes · large randomized prevention trial Read the storyResveratrol has a longevity reputation. Human trials tell a mixed story
One small memory-test signal sits beside several null or unfavorable metabolic trials; human evidence does not show longer life or healthspan.
Human biomarkers and cognitive tests · small heterogeneous trials Read the storyStatin evidence changes with age, risk and prevention setting
Evidence is clearer after vascular disease than for starting primary prevention after age 75, and it does not establish longer life.
Human clinical outcomes · trials and pooled evidence Read the story“Omega-3” is not one intervention—and the trial results do not transfer
Two mixed EPA+DHA trials were neutral on primary outcomes; prescription icosapent ethyl benefited a defined high-risk population with safety and comparator limits.
Human clinical outcomes · formulation-specific randomized trials Read the storyCreatine added to resistance training may improve some strength measures—not longevity
Pooled short trials found modest lean-mass and strength gains, while a related one-year analysis found no additional benefit.
Human function · trials and pooled evidence Read the storySemaglutide reduced cardiovascular events in SELECT—not aging
The randomized result and approved indication are population-specific; anti-aging, healthspan and lifespan claims were not tested.
Human clinical outcomes · large randomized trial Read the storyNAD precursors raise some metabolites; human longevity benefits remain unproven
Small trials show target engagement, not broad clinical, healthspan or lifespan benefit—and products and routes are not interchangeable.
Human biomarkers · small trials Read the storyMetformin is established for diabetes—not for extending healthy human life
Small older-adult studies show mechanistic changes and a blunted hypertrophy signal, not healthspan or lifespan extension.
Human biomarkers and muscle · small trials Read the storyHuman senolytic studies remain small safety and feasibility pilots
Three disease-specific pilot studies do not establish rejuvenation, healthy-person benefit, healthspan or lifespan extension.
Early human safety and feasibility · small pilots Read the storyPEARL trial found no change in its main visceral-fat outcome
The 48-week randomized trial reported a null primary outcome, exploratory signals and substantial limits on broader healthy-aging claims.
Human outcomes · small randomized trial Read the story